Status:
COMPLETED
Does the Bioactive Substance in Coffee, Cafestol, Have Preventive Properties on Type-2-diabetes? (Acute Substudy)
Lead Sponsor:
University of Aarhus
Collaborating Sponsors:
Aarhus University Hospital
Conditions:
Obesity, Abdominal
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Acute, double-blinded, randomized, cross-over cafestol intervention study with fifteen participants with a large waist circumference participating in three OGTTs.
Detailed Description
The study is a acute, double-blinded, randomized, controlled intervention in 15 subjects with abdominal obesity at high risk of developing T2D. Initially, a blood sample is obtained (t=-15 min) and at...
Eligibility Criteria
Inclusion
- 25 \< BMI \< 40 kg/m2 Waist circumference \> 102 cm (men) / 88 cm (women)
Exclusion
- Type 2 diabetes (HbA1c \> 48 mmol/mol) or in treatment with antidiabetic drugs
- Pregnancy
- Planned pregnancy
- Breastfeeding
- Significant comorbidity expected to unable the subject from completing visits
Key Trial Info
Start Date :
May 25 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 16 2021
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT04911582
Start Date
May 25 2021
End Date
September 16 2021
Last Update
February 28 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Steno Diabetes Center Aarhus
Aarhus, Aarhus N, Denmark, 8200